Deucravacitinib (Synonyms: BMS-986165)

Name: Deucravacitinib
Brand: MedChemExpress
SKU: HY-117287
Rating: 5.0 (33 reviews)

Cat. No.: HY-117287 Purity: 99.93%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC₅₀ of 0.2 nM and a K_i of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation. Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus.

For research use only. We do not sell to patients.

CAS No. : 1609392-27-9

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
2 mg	Get quote 2-4 weeks 2-4 weeks 2-4 weeks 2-4 weeks	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	Get quote 2-4 weeks 2-4 weeks 2-4 weeks 2-4 weeks	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	Get quote
10 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 33 publication(s) in Google Scholar

Other Forms of Deucravacitinib:

Deucravacitinib (hydrochloride) Get quote

33 Publications Citing Use of MCE Deucravacitinib

Cell Proliferation/Viability Assay

IHC

In Vivo Efficacy Study

: Deucravacitinib purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2023 Apr 14;29(8):1592-1604. [Abstract]; Deucravacitinib (5-80 μM; 0-72 h). The specific TYK2 inhibitor deucravacitinib (BMS-986165) decreases MPNST cell proliferation at lower doses.

: Deucravacitinib purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2023 Apr 14;29(8):1592-1604. [Abstract]; The combination of drugs inhibiting TYK2 and MEK block MPNST tumor growth in mice. Mice with JW23.3 MPNST xenograft tumors were treated daily with 30 mg/kg deucravacitinib (Deucra, BMS-986165), the combination of drugs, or vehicle control for 3 weeks or until tumors reached the maximum allowed volume.

: Deucravacitinib purchased from MedChemExpress. Usage Cited in: J Invest Dermatol. 2025 Apr 8:S0022-202X(25)00393-8. [Abstract]; BMS-986165 (10 mg/kg; Oral). Representative images of histopathology images taken from each experimental group.

: Deucravacitinib purchased from MedChemExpress. Usage Cited in: Nat Chem Biol. 2022 Dec;18(12):1388-1398. [Abstract]; Western blots measuring effects of VVD-118313 (5a) and BMS-986165 (BMS) (2 µM, 2 h) on JAK1 phosphorylation (pJAK1).

: Deucravacitinib purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2021 Feb;28(2):748-763. [Abstract]; BMS-986165 (0.02-1 μM; 18 h).Cells are treated with the allosteric TYK2 inhibitor BMS-986165 (TYK2 Inh.). BMS-986165 dose-dependently inhibits upregulation of CASP5 in response to LPS in U937 macrophages.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All JAK Isoform Specific Products:

View All Isoforms

JAK1 JAK2 JAK3 Tyk2 JAK

View All STAT Isoform Specific Products:

View All Isoforms

STAT3 STAT5 STAT6 STAT1

View All Interleukin Related Isoform Specific Products:

View All Isoforms

IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

Biological Activity
Purity & Documentation
References
Customer Review

Description

Application

1. This compound can be used as a tracer.
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.

IC₅₀ & Target^[2]

Tyk2

0.2 nM (IC₅₀)

JAK1

1 nM (IC₅₀)

IL-23

IL-12

STAT1

STAT3

In Vitro

Deucravacitinib potently inhibits TYK2-dependent IFNα-induced STAT5 phosphorylation in human CD3⁺ T cells, with an IC₅₀ of 2 nM^[2].
Deucravacitinib potently inhibits TYK2-dependent IL-23-induced STAT3 phosphorylation in human CD161⁺ CD3⁺ T cells, with an IC₅₀ of 9 nM^[2].
Deucravacitinib potently inhibits TYK2-dependent IFNα-induced STAT5 phosphorylation in human whole blood with an IC₅₀ of 13 nM, while exhibiting high functional selectivity for signaling pathways dependent on JAK2, JAK1 and JAK3^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	C_max	AUC	Bioavailability	CL	V_ss	T_1/2	MRT
Mice^[2]	1 mg/kg	i.v.	/	/	/	13.2 mL/min/kg	2.9 L/kg	4.2 h	3.6 h
Mice^[2]	10 mg/kg	p.o.	7.5 μM	36.4 μM·h	122 %	/	/	/	/
Dog^[2]	2 mg/kg	i.v.	/	/	/	6.8 mL/min/kg	2.3 L/kg	4.6 h	5.5 h
Dog^[2]	10 mg/kg	p.o.	6.9 μM	73.6 μM·h	128 %	/	/	/	/
Monkey^[2]	2 mg/kg	i.v.	/	/	/	4.8 mL/min/kg	2 L/kg	5.3 h	7 h
Monkey^[2]	10 mg/kg	p.o.	5.9 μM	75.7 μM·h	87 %	/	/	/	/

In Vivo

Deucravacitinib (7.5-30 mg/kg; p.o.; twice daily; for 9 consecutive days) exhibits dose-dependent efficacy in a mouse IL-23-driven psoriasis model^[2].
Deucravacitinib (50 mg/kg; p.o.; twice daily) almost completely inhibits body weight loss and significantly reduces histological damage in a mouse model of anti-CD40-induced colitis^[2].
Deucravacitinib (30 mg/kg; p.o.; once daily; for 3 consecutive months) is well tolerated in a mouse lupus model and exerts significant efficacy in preventing nephritis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 (PK studies; IL-23-driven acanthosis psoriasis model)^[2]
Dosage:	7.5 mg/kg; 15 mg/kg; 30 mg/kg
Administration:	p.o.; twice daily; 9 days
Result:	Reduced ear thickness increase relative to vehicle, inhibited epidermal hyperplasia and inflammatory cellular infiltration, and dose-dependently reduced relative gene expression of IL-17a, IL-21, IL-23a, IL-23R, IL-12 (p35), and IL-12 (p40) in skin biopsies at 7.5 mg/kg twice daily. Maintained drug levels at or above mouse whole blood IC₅₀ (100 nM) for 19 hours at 7.5 mg/kg twice daily. Achieved ear thickness inhibition equivalent to the anti-IL-23 adnectin positive control, reduced epidermal hyperplasia and inflammatory cellular infiltration, showed greater reduction of cytokine gene expression than the 7.5 mg/kg dose, and maintained drug levels at or above mouse whole blood IC₅₀ for 21 hours at 15 mg/kg twice daily. Provided greater ear thickness protection than the anti-IL-23 adnectin, more effectively inhibited epidermal hyperplasia and inflammatory cellular infiltration than the positive control, showed the greatest reduction of cytokine gene expression across all doses, and maintained drug levels at or above mouse whole blood IC₅₀ for 24 hours at 30 mg/kg twice daily.

Animal Model:	NZB/W (spontaneous lupus-prone nephritis model; treated for three months)^[2]
Dosage:	30 mg/kg
Administration:	p.o.; once daily; three months
Result:	Was well-tolerated, highly efficacious in protecting against nephritis, inhibited type I IFN-dependent gene expression in whole blood and kidneys, and was at least as effective as a blocking anti-IFNαR antibody control; efficacy correlated with coverage of the whole blood IC₅₀ over dosing intervals.

Clinical Trial

Molecular Weight

425.46

Formula

C₂₀H₁₉D₃N₈O₃

CAS No.

1609392-27-9

Unlabeled CAS

2417137-50-7

Appearance

Solid

Color

Off-white to light yellow

SMILES

O=C(C1=NN=C(NC(C2CC2)=O)C=C1NC3=CC=CC(C4=NN(C)C=N4)=C3OC)NC([2H])([2H])[2H]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 33.33 mg/mL (78.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3504 mL	11.7520 mL	23.5040 mL
5 mM	0.4701 mL	2.3504 mL	4.7008 mL
10 mM	0.2350 mL	1.1752 mL	2.3504 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: 3.83 mg/mL (9.00 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.93%

Select Batch:

Data Sheet (282 KB) SDS (418 KB)

COA (253 KB) HNMR (286 KB) RP-HPLC (246 KB)

Handling Instructions (2659 KB)

References

[1]. Armstrong AW, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29-39. [Content Brief]

[2]. Wrobleski ST, et al. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem. 2019;62(20):8973-8995. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.3504 mL	11.7520 mL	23.5040 mL	58.7599 mL
	5 mM	0.4701 mL	2.3504 mL	4.7008 mL	11.7520 mL
	10 mM	0.2350 mL	1.1752 mL	2.3504 mL	5.8760 mL
	15 mM	0.1567 mL	0.7835 mL	1.5669 mL	3.9173 mL
	20 mM	0.1175 mL	0.5876 mL	1.1752 mL	2.9380 mL
	25 mM	0.0940 mL	0.4701 mL	0.9402 mL	2.3504 mL
	30 mM	0.0783 mL	0.3917 mL	0.7835 mL	1.9587 mL
	40 mM	0.0588 mL	0.2938 mL	0.5876 mL	1.4690 mL
	50 mM	0.0470 mL	0.2350 mL	0.4701 mL	1.1752 mL
	60 mM	0.0392 mL	0.1959 mL	0.3917 mL	0.9793 mL

Deucravacitinib Related Classifications

Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Deucravacitinib (Synonyms: BMS-986165)

Customer Review

Other Forms of Deucravacitinib:

Deucravacitinib Related Antibodies

33 Publications Citing Use of MCE Deucravacitinib

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All JAK Isoform Specific Products:

View All STAT Isoform Specific Products:

View All Interleukin Related Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Deucravacitinib Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Deucravacitinib Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report